Vessi Medical Email Formats

Medical Equipment Manufacturing • Misgav Regional Council, North District, Israel • 1-10 Employees

Vessi Medical Email Formats

Vessi Medical uses 2 email formats. The most common is {first name} (e.g., john@vessimed.com), used 66.7% of the time.

Format	Example	Percentage
{first name}	john@vessimed.com	66.7%
{first initial}	j@vessimed.com	33.3%

Key Contact at Vessi Medical

Eyal Kochavi

Ceo & Founder

Company overview

Headquarters	17 Tchelet Street, Misgav, Misgav 2017400, IL
Phone number	+972525235454
Website	vessimed.com
NAICS	3391
Keywords	Urology, Medical Devices, Cryotherapy, Minimally-Invasive, Israeli Startups, In-Office, Bladder-Specific Cryotherapy, Trendlines Group, Disposable Catheter
Employees	1-10
Socials

About Vessi Medical

Vessi Medical is an Israeli medical device startup that brings a new approach to treat urological tissue. The Company uses surface cryotherapy, a treatment that utilizes extreme cold, to freeze and destroy abnormal tissue. THE LEADING STANDARD OF CARE HAS NUMEROUS LIMITATIONS Current invasive surgical procedures, performed under general anaesthesia and requiring a costly hospital stay, can often be inadequate, with increased complications as patients need multiple repeat procedures that further reduce quality of life. VESSI PROVIDES A NEW, OFFICE-BASED THERAPY ALTERNATIVE TO SURGERY Vessi's minimally invasive solution provides a new, office-based therapy alternative to surgery. The company's patent-pending, bladder-specific cryotherapy technology eliminates costly and problematic repeat surgeries. The technology successfully ablates unwanted tissue, reduces complications, all while causing no bladder damage. The Vessi system consists of a standalone console and a disposable catheter that is inserted into the bladder. CHANGING THE STANDARD OF CARE Vessi is backed by the The Trendlines Group, Alive VC and a strategic partner, and led by seasoned medical device and cryotherapy veterans. The company has already demonstrated promising proof of concept in animals with its Alpha product. Vessi’s first application will initially target urological tissue treatments. For more information, please email eyal@vessimed.com.